Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Disease Progression × brigatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 2 Disease Progression 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1

Interventions

umbralisib 1 ublituximab 1 brigatinib 1 binimetinib 1 Zoledronic Acid 1 Vitamin D 1 Irinotecan 1 Calcium 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04005144 2022-10-17

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

University of California, San Francisco

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡